Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
-
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion supporting use of Trelegy Ellipta
-
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
-
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV announced submission of MAA to EMA for a single-tablet, two-drug regimen of DTG and 3TC for the treatment of HIV-1 infection.
-
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GSK will profile the growing evidence base that supports its broad respiratory medicines portfolio at ERS congress in Paris, France, 09/18.
-
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
-
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc(LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab
-
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
-
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen
-
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
-
CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.
-
GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
Advisory Committee provide non-binding recommendation for consideration by the FDA
-
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes
-
GSK delivers improvements in sales, margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
-
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
-
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
-
ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads.
-
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
-
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018
ViiV, specialist HIV company will be presenting over 20 abstracts, including GEMINI 1 & 2 trials, at the AIDS 2018 in Amsterdam.
-
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
There is substantial evidence of the effectiveness and adequate evidence of the safety of single-dose tafenoquine
